Bright Minds Biosciences (DRUG) Cash from Restructuring (2022 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Cash from Restructuring came in at -$19154.8 in Q1 2026, down 211.59% YoY from $17165.1 in Q1 2025, and down 2.64% on a QoQ basis from -$18662.2 in Q4 2025.
Powered by 
Analysis
Bright Minds Biosciences (DRUG) Cash from Restructuring (2022 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 5 years of Cash from Restructuring data on file, last reported at -$19154.8 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Bright Minds Biosciences | 449.62 Mn | 227.08 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19,062.09 |
| Mar 31, 2026 | -19,154.78 |
| Dec 31, 2025 | -18,662.17 |
| Sep 30, 2025 | -126,572.55 |
| Jun 30, 2025 | 18,490.27 |
| Mar 31, 2025 | 17,165.05 |
| Dec 31, 2024 | 17,030.05 |
| Sep 30, 2024 | -114,063.84 |
| Jun 30, 2024 | 16,053.65 |
| Mar 31, 2024 | 16,294.58 |
| Dec 31, 2023 | 16,128.20 |
| Sep 30, 2023 | -112,321.46 |
| Jun 30, 2023 | 15,997.54 |
| Mar 31, 2023 | 15,896.07 |
| Dec 31, 2022 | 15,830.27 |